ProPhase Labs Inc (NASDAQ:PRPH)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $3.46, but opened at $4.07. ProPhase Labs shares last traded at $3.92, with a volume of 201 shares traded.
PRPH has been the subject of several recent research reports. TheStreet raised ProPhase Labs from a “d+” rating to a “c” rating in a report on Wednesday, August 19th. ValuEngine cut ProPhase Labs from a “buy” rating to a “hold” rating in a research note on Wednesday, August 12th.
The business has a 50-day simple moving average of $3.01 and a two-hundred day simple moving average of $2.01.
ProPhase Labs (NASDAQ:PRPH) last released its quarterly earnings results on Tuesday, August 11th. The company reported $0.01 earnings per share for the quarter. ProPhase Labs had a negative return on equity of 13.52% and a negative net margin of 14.31%. The firm had revenue of $3.62 million during the quarter.
In other news, CEO Ted William Karkus sold 50,000 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $2.75, for a total value of $137,500.00. Following the completion of the sale, the chief executive officer now owns 2,419,528 shares of the company’s stock, valued at approximately $6,653,702. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 30.90% of the company’s stock.
ProPhase Labs Company Profile (NASDAQ:PRPH)
ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.
Featured Article: What is the definition of market timing?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.